B
Biodol Therapeutics
Develops first-in-class compounds for the treatment of chronic pain
About Biodol Therapeutics
Biodol Therapeutics, established in 2015, is a French clinical-stage biotechnology company focused on creating treatments for chronic pain. The company's foundation is built upon the discovery that the Receptor Tyrosine Kinase (RTK) FLT3 is a critical component in the initiation and persistence of neuropathic pain. This scientific breakthrough originated from the academic research of its founders, including Didier Rognan, Research Director at CNRS, and Jean Valmier, a professor at the University of Montpellier, whose work was published in Nature Communications in 2018. The leadership team includes CEO Fabien Granier, who has extensive experience in managing and fundraising for biotech companies, and CSO Pierre Sokoloff, a former R&D director at Pierre Fabre Laboratories.
The company's primary business is the research and development of first-in-class, small-molecule drugs that target FLT3. Biodol's business model revolves around advancing its drug candidates through preclinical and early clinical stages before potentially out-licensing them to larger pharmaceutical partners for late-stage development and commercialization. The company has secured its intellectual property with a portfolio of patents, co-owned with French research institutions like CNRS and INSERM, covering the use of FLT3 inhibitors for pain and in combination with opioids.
Biodol's lead product candidate, BDT272, is an oral, extracellular negative allosteric modulator (NAM) of the FLT3 receptor. This mechanism is designed to offer higher selectivity and an improved safety profile compared to less specific intracellular kinase inhibitors, which can have significant side effects. BDT272 is being developed as both a non-opioid monotherapy for neuropathic pain conditions and as an adjuvant therapy to be used with opioids. Research has shown that inhibiting FLT3 can enhance the analgesic effects of morphine while preventing the development of tolerance and hyperalgesia, addressing a major challenge in the opioid crisis. In May 2024, the company announced it had secured €7 million in a mix of equity and non-dilutive funding, led by venture capital fund V-Bio Ventures and BPI France, to advance BDT272 into first-in-human clinical trials.
Source: Dealroom company dataAt a glance
- Founded
- 2015
- Headquarters
- Clapiers, France
- Sector
- Biotech & Life Sciences
News
Open roles
Biodol Therapeutics in the Clapiers ecosystem
The Biodol Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
V-Bio Ventures
Bpifrance
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Biodol Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biodol Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

